Limiting the amount of RAM used by the TCP/IP stack in embedded systems improves the device’s security and reliability.

From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...

A major crisis is brewing in the opposition coalition under the African Democratic Congress, ADC, as the party suspended its National Vice Chairman, South-South, and former Minister of Niger Delta ...

As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, the German biotech has secured a massive new financing round to kick its ...

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody ...

The African Democratic Congress has cautioned the National Assembly against its proposed plan to amend the Electoral Act and shift the 2027 general elections to November 2026, warning that such a move ...

The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate ...

Abuja—The presidential candidate of Labour Party in the 2023 election, Peter Obi, African Democratic Congress, ADC, and the senator representing Bayelsa West, Seriake Dickson, yesterday railed the ...

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...

BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

Takeda Pharmaceutical is bolstering its pipeline in a big way, committing $1.2 billion for rights to two late-stage Innovent Biologics cancer drugs and securing an exclusive option to license an early ...